Literature DB >> 28401191

Inhibition of EZH2 degradation as a novel approach to overcome drug resistance in acute myeloid leukemia.

Stefanie Göllner1, Carsten Müller-Tidow1.   

Abstract

The polycomb protein enhancer of zeste homolog 2 (EZH2) may have a dual role in cancer pathogenesis acting as an oncogene or as a tumor suppressor depending on the cancer type. We recently demonstrated that proteasomal degradation of EZH2 resulting from cyclin-dependent kinase 1 (CDK1)-induced phosphorylation at Threonine (T) 487 represents a novel mechanism of drug resistance in acute myeloid leukemia (AML). Our findings suggest that restoration of EZH2 protein is a viable approach to overcome therapy resistance in AML.

Entities:  

Keywords:  Acute myeloid leukemia (AML); EZH2; drug resistance; epigenetic; proteasome

Year:  2017        PMID： 28401191      PMCID： PMC5383362          DOI： 10.1080/23723556.2017.1291396

Source DB:  PubMed          Journal:  Mol Cell Oncol        ISSN： 2372-3556


  10 in total

1.  ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category.

Authors:  Klaus H Metzeler; Heiko Becker; Kati Maharry; Michael D Radmacher; Jessica Kohlschmidt; Krzysztof Mrózek; Deedra Nicolet; Susan P Whitman; Yue-Zhong Wu; Sebastian Schwind; Bayard L Powell; Thomas H Carter; Meir Wetzler; Joseph O Moore; Jonathan E Kolitz; Maria R Baer; Andrew J Carroll; Richard A Larson; Michael A Caligiuri; Guido Marcucci; Clara D Bloomfield
Journal:  Blood       Date:  2011-10-26       Impact factor: 22.113

2.  TET2 mutation is an unfavorable prognostic factor in acute myeloid leukemia patients with intermediate-risk cytogenetics.

Authors:  Wen-Chien Chou; Sheng-Chieh Chou; Chieh-Yu Liu; Chien-Yuan Chen; Hsin-An Hou; Yuan-Yeh Kuo; Ming-Cheng Lee; Bor-Sheng Ko; Jih-Luh Tang; Ming Yao; Woei Tsay; Shang-Ju Wu; Shang-Yi Huang; Szu-Chun Hsu; Yao-Chang Chen; Yi-Chang Chang; Yi-Yi Kuo; Kuan-Ting Kuo; Fen-Yu Lee; Ming-Chi Liu; Chia-Wen Liu; Mei-Hsuan Tseng; Chi-Fei Huang; Hwei-Fang Tien
Journal:  Blood       Date:  2011-08-09       Impact factor: 22.113

3.  Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders.

Authors:  Thomas Ernst; Andrew J Chase; Joannah Score; Claire E Hidalgo-Curtis; Catherine Bryant; Amy V Jones; Katherine Waghorn; Katerina Zoi; Fiona M Ross; Andreas Reiter; Andreas Hochhaus; Hans G Drexler; Andrew Duncombe; Francisco Cervantes; David Oscier; Jacqueline Boultwood; Francis H Grand; Nicholas C P Cross
Journal:  Nat Genet       Date:  2010-07-04       Impact factor: 38.330

4.  Mutant DNMT3A: a marker of poor prognosis in acute myeloid leukemia.

Authors:  Ana Flávia Tibúrcio Ribeiro; Marta Pratcorona; Claudia Erpelinck-Verschueren; Veronika Rockova; Mathijs Sanders; Saman Abbas; Maria E Figueroa; Annelieke Zeilemaker; Ari Melnick; Bob Löwenberg; Peter J M Valk; Ruud Delwel
Journal:  Blood       Date:  2012-04-05       Impact factor: 22.113

Review 5.  Molecular mechanisms of drug resistance.

Authors:  D B Longley; P G Johnston
Journal:  J Pathol       Date:  2005-01       Impact factor: 7.996

6.  Bortezomib added to daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine for consolidation in patients with previously untreated acute myeloid leukemia age 60 to 75 years: CALGB (Alliance) study 10502.

Authors:  Eyal C Attar; Jeffrey L Johnson; Philip C Amrein; Gerard Lozanski; Martha Wadleigh; Daniel J DeAngelo; Jonathan E Kolitz; Bayard L Powell; Peter Voorhees; Eunice S Wang; William Blum; Richard M Stone; Guido Marcucci; Clara D Bloomfield; Barry Moser; Richard A Larson
Journal:  J Clin Oncol       Date:  2012-11-05       Impact factor: 44.544

7.  Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models.

Authors:  Eloisi Caldas-Lopes; Leandro Cerchietti; James H Ahn; Cristina C Clement; Ana I Robles; Anna Rodina; Kamalika Moulick; Tony Taldone; Alexander Gozman; Yunke Guo; Nian Wu; Elisa de Stanchina; Julie White; Steven S Gross; Yuliang Ma; Lyuba Varticovski; Ari Melnick; Gabriela Chiosis
Journal:  Proc Natl Acad Sci U S A       Date:  2009-05-05       Impact factor: 11.205

8.  Cyclin-dependent kinase 1 (CDK1)-mediated phosphorylation of enhancer of zeste 2 (Ezh2) regulates its stability.

Authors:  Susan C Wu; Yi Zhang
Journal:  J Biol Chem       Date:  2011-06-09       Impact factor: 5.157

9.  Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin.

Authors:  Ryan D Morin; Nathalie A Johnson; Tesa M Severson; Andrew J Mungall; Jianghong An; Rodrigo Goya; Jessica E Paul; Merrill Boyle; Bruce W Woolcock; Florian Kuchenbauer; Damian Yap; R Keith Humphries; Obi L Griffith; Sohrab Shah; Henry Zhu; Michelle Kimbara; Pavel Shashkin; Jean F Charlot; Marianna Tcherpakov; Richard Corbett; Angela Tam; Richard Varhol; Duane Smailus; Michelle Moksa; Yongjun Zhao; Allen Delaney; Hong Qian; Inanc Birol; Jacqueline Schein; Richard Moore; Robert Holt; Doug E Horsman; Joseph M Connors; Steven Jones; Samuel Aparicio; Martin Hirst; Randy D Gascoyne; Marco A Marra
Journal:  Nat Genet       Date:  2010-01-17       Impact factor: 38.330

10.  Loss of the histone methyltransferase EZH2 induces resistance to multiple drugs in acute myeloid leukemia.

Authors:  Stefanie Göllner; Thomas Oellerich; Shuchi Agrawal-Singh; Tino Schenk; Hans-Ulrich Klein; Christian Rohde; Caroline Pabst; Tim Sauer; Mads Lerdrup; Sigal Tavor; Friedrich Stölzel; Sylvia Herold; Gerhard Ehninger; Gabriele Köhler; Kuan-Ting Pan; Henning Urlaub; Hubert Serve; Martin Dugas; Karsten Spiekermann; Binje Vick; Irmela Jeremias; Wolfgang E Berdel; Klaus Hansen; Arthur Zelent; Claudia Wickenhauser; Lutz P Müller; Christian Thiede; Carsten Müller-Tidow
Journal:  Nat Med       Date:  2016-12-12       Impact factor: 53.440
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.